NSCLC

ASCO Updates Systemic Therapy Guideline for NSCLC With Driver Alterations

03/09/2021

Janelle Bradley

The American Society of Clinical Oncology released an update to its guideline on systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations.

The American Society of Clinical...

03/09/2021

Journal of Clinical Pathways

Research in Review

Equivalent Outcomes With Two NSCLC Treatment Options

08/04/2016

JCP Editors

Erlotinib may be an effective therapeutic option for patients with pretreated advanced non-small cell lung cancer (NSCLC) and no known molecular alterations, according to a study published in the journal Lung...

...

08/04/2016

Journal of Clinical Pathways

Research in Review

Cost-Effectiveness of Two NSCLC Treatments Compared

07/15/2016

JCP Editors

Compared with docetaxel, nivolumab is not a cost-effective treatment option for nonsquamous non-small cell lung cancer unless its price is reduced or it is used after programmed death ligand 1 (PD-L1) testing,...

...

07/15/2016

Journal of Clinical Pathways

Quality Measures for NSCLC Significantly Improve Survival

05/20/2016

JCP Editors

Including certain quality measures as a part of care for patients with non-small cell lung cancer (NSCLC) who undergo surgery can significantly improve survival, according to results presented at the American...

...

05/20/2016

Journal of Clinical Pathways

Research in Review

Blood Biopsy Test Ready for Use in Patients With NSCLC

04/14/2016

JCP Editors

A newly developed “liquid biopsy” assay that detects free-floating DNA from cells in blood plasma may be an effective tool for detecting mutations in patients with non-small cell lung cancer (NSCLC), according to the...

A...

04/14/2016

Journal of Clinical Pathways